Menu Search
Equities

Certara Inc

700:BER

Certara Inc

Actions
  • Price (EUR)9.91
  • Today's Change0.594 / 6.37%
  • Shares traded600.00
  • 1 Year change-28.17%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 17:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Certara, Inc. is engaged in model-informed drug development. The Company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to efficiently carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services are underpinned by technologies such as regulatory submissions software, natural language processing and Bayesian analytics. It also develops scientific informatics software products used by the life sciences industry for in-silico research. It develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 66 countries.

  • Revenue in USD (TTM)372.80m
  • Net income in USD-31.08m
  • Incorporated2017
  • Employees1.34k
  • Location
    Certara Inc4 Radnor Corporate Center, Suite 350RADNOR 19087United StatesUSA
  • Phone+1 (415) 237-8272
  • Fax+1 (302) 636-5454
  • Websitehttps://www.certara.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		CERT:NSQ since
announced		Transaction
value
ChemAxon LtdDeal completed09 Jul 202409 Jul 2024Deal completed-27.55%--
Data delayed at least 15 minutes, as of Nov 22 2024 18:28 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.